Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback